Browsing Tag
Tempus AI
17 posts
Brainomix appoints Khush F. Mehta as Chair to accelerate global ai healthcare expansion
Brainomix names Khush F. Mehta as Chair to drive U.S. and global expansion after $18M funding and FDA clearance for its AI stroke platform.
Top U.S. gainers: Regencell, Disney, Rockwell, and Tempus AI spark broad market rally
Explore which U.S. stocks surged on May 7, 2025, and why investors rotated into biotech, AI, and healthcare amid Fed pauses and macro uncertainty.
AI just got personal: Illumina and Tempus team up to make DNA testing part of every doctor’s visit
Find out how Illumina and Tempus are transforming healthcare with AI-driven genomic tools to advance precision medicine across cancer, cardiology, and more.
Tech and AI stocks plunge as market selloff hits Core Scientific, Vertiv, Root, and more
Tech and AI stocks tumbled on March 26, 2025, as trade tariffs and market uncertainty triggered a selloff. Find out which stocks were the biggest losers.
Tempus AI and Stemline Therapeutics partner to advance AI-driven ESR1 mutation testing in metastatic breast cancer
Tempus AI, Inc. (NASDAQ: TEM) and Stemline Therapeutics, Inc., a wholly owned subsidiary of the Menarini Group, have…
Tempus AI stock soars 14% after FDA approval of xT CDx test
Tempus AI, a leader in healthcare technology, has unveiled its FDA-approved in vitro diagnostic device, xT CDx, marking…
Tempus AI shakes up precision medicine with $600m acquisition of Ambry Genetics
Tempus AI has taken a significant step in advancing its precision medicine strategy by agreeing to acquire Ambry…